MimiVax reports Phase II data for glioblastoma immunotherapy

MimiVax LLC (Buffalo, N.Y.) reported interim data from a Phase II trial in 63 newly diagnosed glioblastoma patients showing that subcutaneous SurVaxM led to a six-month progression-free survival (PFS) rate of 96.3% and a 12-month overall survival (OS) rate of 90.9% compared with 54% and 61%, respectively, for historical standard of care (SOC). The data were released late on May 16 in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. MimiVax reported additional updates in a press release on May 21.

Patients in the open-label, U.S. trial received four priming doses of 500 μg SurVaxM in emulsion with adjuvant Montanide ISA 51 plus Leukine sargramostim every two weeks, followed by adjuvant temozolomide and maintenance SurVaxM every 12 weeks. Final data from the trial are expected in 4Q18...